For whoever it was who was keen to see the actual reimbursement differential between canaloplasty and stents, here is something I found that clearly explains the significance of the significantly higher reimbursement for canaloplasty relative to stents. I can imagine why Glaukos was so frustrated, it's an enormous difference!
Note the changes to reimbursement only came in 2022, so this should be a significant driver of revenue growth in addition to the improvements made to the iTrack procedure itself.
Nova Eye Medical (EYE) Discussion, page-955
-
- There are more pages in this discussion • 2,233 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EYE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.0¢ |
Change
0.010(5.56%) |
Mkt cap ! $43.52M | |||
| Open | High | Low | Value | Volume |
| 18.5¢ | 19.5¢ | 18.5¢ | $12.62K | 66.11K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 49388 | 19.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.5¢ | 63159 | 2 |
View Market Depth
| Last trade - 12.20pm 18/10/2024 (20 minute delay) ? |
| EYE (ASX) Chart |